MIRA Pharmaceuticals Inc. saw its stock surge after revealing promising preclinical data for its lead development product, Ketamir-2. This novel oral Ketamine analog achieved a 100% reversal of neuropathic pain in preclinical models, potentially offering a significant advancement in pain management. The company is aiming for human trials by 2025.